Indivior Pharmaceuticals
INDV
259 hedge funds and large institutions have $4.36B invested in Indivior Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 90 funds opening new positions, 84 increasing their positions, 67 reducing their positions, and 26 closing their positions.
1,820% more call options, than puts
Call options by funds: $78M | Put options by funds: $4.07M
246% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 26
63% more capital invested
Capital invested by funds: $2.68B → $4.36B (+$1.68B)
31% more funds holding
Funds holding: 198 → 259 (+61)
25% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 67
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$290M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$97.8M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$70.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$56.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
-$7.65B |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
-$165M |
| 3 |
DM
Deerfield Management
New York
|
-$110M |
| 4 |
Goldman Sachs
New York
|
-$104M |
| 5 |
NM
Newtyn Management
New York
|
-$50.9M |
INDV Hedge Fund Activity: Q4 2025 in Review
259 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Indivior Pharmaceuticals (INDV) for Q4 2025, worth a combined $4.36B — up 63% from $2.68B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new INDV positions and 26 closed out — a net gain of 64 holders — while 84 added to existing stakes and 67 trimmed.
The largest buyer was BlackRock, adding an estimated $290M. The largest seller was Oaktree Capital Management, cutting an estimated $7.65B.
- 259 institutional investors held Indivior Pharmaceuticals (INDV) as of Q4 2025, up from 198 in Q3 2025.
- Funds reported $4.36B of Indivior Pharmaceuticals stock for Q4 2025, up 63% quarter-over-quarter.
- 90 funds opened new Indivior Pharmaceuticals positions in Q4 2025 and 26 closed out, a net change of +64 holders.
- The largest Indivior Pharmaceuticals buyer in Q4 2025 was BlackRock, an estimated $290M added.
- The largest Indivior Pharmaceuticals seller in Q4 2025 was Oaktree Capital Management, an estimated $7.65B sold.
Based on aggregated 13F filings for Q4 2025.